triple negative breast cancer

News

FDA knocks back AstraZeneca's self-injected lupus drug

FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.

Oncology

Advances in breast cancer: What’s new from ESMO 2025

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.

News

ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy

Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.

News

Delayed TNBC readout for Datroway delivers survival benefit

AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

News

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

FDA knocks back AstraZeneca's self-injected lupus drug

Advances in breast cancer: What’s new from ESMO 2025

ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy

Delayed TNBC readout for Datroway delivers survival benefit

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Trodelvy-Keytruda pairing hits the spot in breast cancer

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

triple negative breast cancer

Editor's Picks